Editas Medicine Stock Forecast, Price & News

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EDIT shares have increased by 52.6% and is now trading at $30.94.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Editas Medicine.

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Editas Medicine.

Editas Medicine will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Editas Medicine Inc (NASDAQ:EDIT) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.43) EPS for the quarter, topping the Zacks' consensus estimate of ($0.80) by $0.37. The business had revenue of $10.75 million for the quarter, compared to analysts' expectations of $6.34 million. Editas Medicine had a negative net margin of 404.88% and a negative return on equity of 46.57%. The company's quarterly revenue was up 361.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.69) earnings per share.
View Editas Medicine's earnings history.

7 equities research analysts have issued 1 year price targets for Editas Medicine's stock. Their forecasts range from $28.00 to $65.00. On average, they anticipate Editas Medicine's share price to reach $44.80 in the next year. This suggests a possible upside of 44.8% from the stock's current price.
View analysts' price targets for Editas Medicine.

Some companies that are related to Editas Medicine include Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Vir Biotechnology (VIR), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), Immunovant (IMVT) and Ablynx (ABLYF).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (17.14%), State of Michigan Retirement System (0.31%), State of New Jersey Common Pension Fund D (0.11%), WINTON GROUP Ltd (0.07%), Crestwood Advisors Group LLC (0.05%) and BNP Paribas Arbitrage SA (0.03%). Company insiders that own Editas Medicine stock include Andrew A F Hack, Charles Albright, Cynthia Collins, Jessica Hopfield, Katrine Bosley and Vickesh Myer.
View institutional ownership trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Cambridge Investment Research Advisors Inc., Focused Wealth Management Inc, and Crestwood Advisors Group LLC. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, and Cynthia Collins.
View insider buying and selling activity for Editas Medicine.

EDIT stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, State of Michigan Retirement System, WINTON GROUP Ltd, DekaBank Deutsche Girozentrale, Patriot Financial Group Insurance Agency LLC, Exchange Traded Concepts LLC, BNP Paribas Arbitrage SA, and Pacer Advisors Inc..
View insider buying and selling activity for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $30.94.

Editas Medicine has a market capitalization of $1.93 billion and generates $20.53 million in revenue each year. The company earns $-133,750,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Editas Medicine employs 133 workers across the globe.

The official website for Editas Medicine is www.editasmedicine.com.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]